NEW YORK (GenomeWeb News) – Pathway Genomics, a new direct-to-consumer genetic testing firm, launched today, offering genotyping and analysis for disease risk and heredity for under $250.

The San Diego, Calif.-based company said that its on-site lab has been certified by California regulators and has received CLIA clearance. The company said its testing enables customers to learn about disease risk, adverse drug responses, carrier status, and ancestral history.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.